Lennol, Matthew Paul
Sánchez-Domínguez, Irene
Cuchillo-Ibañez, Inmaculada
Camporesi, Elena
Brinkmalm, Gunnar
Alcolea, Daniel
Fortea, Juan
Lleó, Alberto
Soria, Guadalupe
Aguado, Fernando
Zetterberg, Henrik
Blennow, Kaj
Sáez-Valero, Javier
Funding for this research was provided by:
Conselleria d'Educació, Investigació, Cultura i Esport (ACIF/2019/062, ACIF/2019/062)
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (PI15/00665, PI15/00665, PI15/00665)
Fundación Carmen y Severo Ochoa (SEV-2017-0723, SEV-2017-0723, SEV-2017-0723)
Ministerio de Ciencia, Innovación y Universidades (PID2019-107738RB-I00, PID2019-107738RB-I00, PID2019-107738RB-I00)
Swedish State Support for Clinical Research (ALFGBG-720931, ALFGBG-720931, ALFGBG-720931)
Alzheimer's Drug Discovery Foundation (201809-2016862, 201809-2016862, 201809-2016862, RDAPB-201809-2016615)
Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, ZEN-21-848495)
Instituto de Salud Carlos III (PI14/01126, PI17/01019, PI20/01473 and INT16/00171, PI18/00435, PI14/1561, PI17/01896 and PI20/1330, PI18/00893)
Generalitat de Catalunya (SLT006/17/00125, SLT006/17/00119)
National Institutes of Health (1R01AG056850-01A1; R21AG056974 and R01AG061566, 1R01AG068398-01)
Departament de Salut, Generalitat de Catalunya (SLT002/16/00408)
Vetenskapsrådet (2018-02532, 2017-00915)
European Research Council (681712)
Stiftelsen för Gamla Tjänarinnor (FO2019-0228)
Horizon 2020 Framework Programme (860197)
European Union Joint Programme - Neurodegenerative Disease Research (JPND2021-00694)
UK Dementia Research Institute (UKDRI-1003)
Swedish Alzheimer Foundation (AF-742881)
Hjärnfonden (FO2017-0243)
VINNOVA (ALFGBG-715986)
European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)
Article History
Received: 3 May 2022
Accepted: 16 October 2022
First Online: 2 November 2022
Declarations
:
: This study was approved by the ethics committee at the Miguel Hernandez University (ref# UMH.iNJS.01.18), and it was carried out in accordance with the Helsinki Declaration regarding research on humans. The present assays were performed on de-identified left-over aliquots from clinical diagnostic CSF samples; thus, no consent for participation was required. The samples were obtained following procedures approved by the Ethics Committees at the University of Gothenburg and the Hospital Sant Pau, respectively. Animal work was performed in accordance with the local legislation, with the approval of the Experimental Animal Ethical Committee of the University of Barcelona, and in compliance with European legislation.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper. JF has served as a consultant for Novartis and Lundbeck; has received honoraria for lectures from Roche, NovoNordisk, Nestle, Esteve, and Biogen; and served at advisory boards for AC Immune, Zambon, and Lundbeck. D.A. participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U., and Esteve Pharmaceuticals S.A. AL has served at scientific advisory boards from Fujirebio-Europe, Nutricia, Roche-Genentech, Biogen, Grifols, and Roche Diagnostics and has filed a patent application of synaptic markers in neurodegenerative diseases.